§01 Browse › Retatrutide

Retatrutide

GLP-1/GIP/glucagon triple agonist LY3437943
Research Compound
Cutting

This profile covers Retatrutide. Start with the peptide's intended use, human evidence and product-quality limitations before the mechanism details.

Technical catalog description

Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptor pathways simultaneously. In phase 2 trials it produced weight loss of approximately 24% of body weight over 48 weeks, exceeding tirzepatide and semaglutide in head-to-head comparisons. The addition of glucagon receptor agonism accelerates lipolysis and energy expenditure beyond what GLP-1 and GIP activation alone produce.

Overview Use context Comparison Safety
Warning
Still in clinical trials; long-term safety data is unavailable · Glucagon agonism increases resting heart rate in some users · Potent appetite suppression requires deliberate protein and electrolyte intake to preserve lean mass

Read next

Intro to Peptides 6 min readThe Philosophy and Practice of Harm Reduction 9 min readGLP-1 Drugs: Semaglutide, Tirzepatide, and Retatrutide 5 min read
More depthPeptide Reconstitution and Injection Math
Overview

Retatrutide is the most aggressive end of the current incretin conversation because it combines GLP-1, GIP, and glucagon receptor agonism. That third pathway is what makes it different. It is also what makes it harder to treat like a simple stronger version of semaglutide or tirzepatide.

The promise is greater bodyweight reduction and more energy-expenditure drive. The cost is a thinner evidence base, more uncertainty around long-term tolerability, and a greater need to pay attention to hydration, resting heart rate, and lean-mass retention while bodyweight drops.

Safety & monitoring
Side effects

  • GI upset, higher heart rate, rapid weight-loss pace, and uncertain long-term tolerability

  • More potent appetite suppression than many users can manage intelligently

Monitoring

  • bodyweight trend

  • resting heart rate

  • fasting glucose / HbA1c

Avoid if

  • Users who cannot tolerate aggressive appetite suppression or fast bodyweight change

  • Treating an investigational drug like a routine supplement

Use context

Retatrutide is chosen because it looks like the next step beyond Semaglutide and Tirzepatide. It attracts users who want the most aggressive currently discussed pharmaceutical-style fat-loss option and are willing to accept that the real-world safety picture is still early.

Timeline & expectations

Expectations should stay disciplined. Early trial results are impressive, but impressive weight loss is not the same thing as clean body-composition improvement. If appetite suppression outruns protein intake, hydration, and training quality, the result can still be a worse physique at a lower bodyweight.

Common mistakes

The main mistake is treating early clinical excitement as mature long-term safety evidence. The second is letting rapid bodyweight loss outpace the user’s ability to preserve muscle, hydration, and performance.

Comparison notes

Compared with Semaglutide and Tirzepatide, retatrutide usually promises more. It also asks the user to tolerate a thinner evidence base, greater uncertainty, and less room to act as though the compound is already fully understood.

Record quantities in the builder Read: Intro to Peptides ← Browse